MD3940G2 - Metodă de tratament al paraliziei plexului brahial - Google Patents

Metodă de tratament al paraliziei plexului brahial Download PDF

Info

Publication number
MD3940G2
MD3940G2 MDA20080101A MD20080101A MD3940G2 MD 3940 G2 MD3940 G2 MD 3940G2 MD A20080101 A MDA20080101 A MD A20080101A MD 20080101 A MD20080101 A MD 20080101A MD 3940 G2 MD3940 G2 MD 3940G2
Authority
MD
Moldova
Prior art keywords
days
day
homaccord
biologically active
compositum
Prior art date
Application number
MDA20080101A
Other languages
English (en)
Russian (ru)
Other versions
MD3940F1 (ro
Inventor
Светлана ХАДЖИУ
Original Assignee
Светлана ХАДЖИУ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Светлана ХАДЖИУ filed Critical Светлана ХАДЖИУ
Priority to MDA20080101A priority Critical patent/MD3940G2/ro
Publication of MD3940F1 publication Critical patent/MD3940F1/ro
Publication of MD3940G2 publication Critical patent/MD3940G2/ro

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Invenţia se referă la medicină, neurologie, pediatrie şi este destinată tratamentului paraliziilor plexului brahial la nou-născuţi şi sugari.Metoda, conform invenţiei, constă în aceea că se administrează per os Bryaconeel şi Nervoheel câte ¼… 1/2 pastilă de 3 ori pe zi timp de 1 lună; Cinnamomum-Homaccord N, Lymphomyosot şi Galium-Heel N de 3 ori pe zi câte 3…5 picături timp de 1 lună; subcutanat Traumeel S câte 0,4…0,8 ml zilnic în primele 3 zile, apoi peste 1 zi, Cerebrum Compositum N câte 0,4…0,8 ml peste 3 zile, Gelsemium-Homaccord câte 0,3…0,5 ml peste 2 zile, Ferrum-Homaccord câte 0,3…0,5 ml peste 3 zile, Circulo-Injeel câte 0,3…0,6 ml de 2 ori pe săptămână, la o serie de tratament de 7…10 injecţii, de asemenea Coenzyme compositum şi Ubichinon Compositum câte 0,3…0,5 ml o dată pe săptămână, la o serie de tratament de 2…4 injecţii. Totodată, preparatele menţionate se administrează în următoarele puncte biologic active: T14; V11; IG 2-8, 12,15; VB21; G 5-12, 14-15; P5,9; C3-8; MC3-9; TR3-10; AP37,41,55,63,64,65,66. În fiecare punct biologic activ se introduce un singur preparat medicamentos menţionat câte 0,1…0,3 ml, care se administrează în 3…5 puncte, totodată în fiecare zi se selectează diferite puncte biologic active.
MDA20080101A 2008-04-07 2008-04-07 Metodă de tratament al paraliziei plexului brahial MD3940G2 (ro)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20080101A MD3940G2 (ro) 2008-04-07 2008-04-07 Metodă de tratament al paraliziei plexului brahial

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20080101A MD3940G2 (ro) 2008-04-07 2008-04-07 Metodă de tratament al paraliziei plexului brahial

Publications (2)

Publication Number Publication Date
MD3940F1 MD3940F1 (ro) 2009-07-31
MD3940G2 true MD3940G2 (ro) 2010-02-28

Family

ID=40941130

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20080101A MD3940G2 (ro) 2008-04-07 2008-04-07 Metodă de tratament al paraliziei plexului brahial

Country Status (1)

Country Link
MD (1) MD3940G2 (ro)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59569A (uk) * 2002-08-08 2003-09-15 В'ячеслав Євгенович Сотниченко Спосіб лікування хворих з паралічем плечового сплетіння та пристрій для його здійснення

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59569A (uk) * 2002-08-08 2003-09-15 В'ячеслав Євгенович Сотниченко Спосіб лікування хворих з паралічем плечового сплетіння та пристрій для його здійснення

Also Published As

Publication number Publication date
MD3940F1 (ro) 2009-07-31

Similar Documents

Publication Publication Date Title
NZ630790A (en) Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP2016514132A5 (ro)
PH12021551747A1 (en) Composition for treating diabetes, containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
HU3526U (en) Blister card
MD3940G2 (ro) Metodă de tratament al paraliziei plexului brahial
MD3803G2 (ro) Metodă de tratament al hiperchineziilor la copii
Berenson et al. Pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma: results from a phase 1/2 trial
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
CN105232577A (zh) 一种脂肪来源干细胞因子的生发技术
PH12014502494A1 (en) Parenteral esmolol formulation
MD3927G2 (ro) Metodă de tratament al paraliziei faciale
Lozano-Blasco Immune globulin
Time Clinical Trials of Interferon Alfa in Locally Advanced or Metastatic Renal Cell Carcinoma
Schaub et al. Pharmacokinetics and Pharmacodynamics after Subcutaneous Dosing of the iNKT Cell Depleting Antibody NKTT120
UA47304U (ru) Способ лечения хронических рецидивирующих пиодермий
UA64881U (ru) Способ лечения печеночной недостаточности пострадавших с травмой печени
Song Arsenic trioxide
Koch Hyperthyroidism and radioiodine
UA37228U (ru) Способ лечения фетоплацентарной недостаточности у беременных с гипертензивными расстройствами
Carlson Metastatic Colorectal Cancer: TAS-102, Regorafenib Trials ‘Unequivocally Positive’
MX2019009733A (es) 3'-deamino-3'-(2''-pirrolin-1''-il)-5-imino-13-desoxiantraciclina s y metodos de preparacion.
Park Delayed hypersensitivity: case report
Miyoshi Autologous formalin fixed tumour cell vaccine/pembrolizumab

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees